SHORTList
Chai Discovery, Inc. logo
AI/ML
Biotech/Pharma

Chai Discovery, Inc.

AI-driven molecular drug discovery

CORE INFO

$225M
Total Funding
Series B
Round
2024
Founded
51
Team Size
San Francisco, California, USA
Headquarters

Chai Discovery, Inc. is a pioneering biotechnology company that leverages artificial intelligence to transform the landscape of drug discovery. By focusing on the design of novel molecules, particularly antibodies, Chai Discovery aims to enhance therapeutic properties and streamline the development of new therapeutics. Their AI models are designed to predict and reprogram interactions between biochemical molecules, effectively transforming biology from a science into an engineering discipline. Founded in 2024 and headquartered in San Francisco, California, Chai Discovery has quickly made a name for itself in the biotech and pharmaceutical industries. The company has developed advanced AI models, such as Chai-2, which have significantly improved success rates in de novo antibody design. This innovation has led to a partnership with pharmaceutical giant Eli Lilly, underscoring Chai Discovery's growing influence in AI-driven drug development.

WHY WE WOULD WORK AT CHAI DISCOVERY, INC.

Innovative AI Models

Work with cutting-edge AI models like Chai-2, revolutionizing antibody design with unprecedented success rates.

Rapid Growth Potential

Join a fast-growing biotech startup backed by $225M in funding and a partnership with Eli Lilly.

Transforming Drug Discovery

Contribute to a mission that turns biology into engineering, accelerating therapeutic development.

Collaborative Team Culture

Be part of a dynamic team of 51 innovators, fostering collaboration and creativity in San Francisco.

Industry Recognition

Gain recognition working at a company celebrated for its AI-driven breakthroughs in the biotech sector.

Competitive Compensation

Benefit from attractive compensation packages, reflecting the company's commitment to valuing its talent.

MARKET AND TRACTION

GROWTH TACTICS

  • Chai Discovery leverages advanced AI models to enhance the success rates of de novo antibody design, positioning itself as a leader in AI-driven drug discovery.

  • The company has secured significant funding, with a total of $225 million raised across multiple rounds, enabling rapid expansion and technological advancements.

  • Strategic partnerships, such as the one with Eli Lilly, underscore Chai Discovery's commitment to collaborative growth and industry influence.

    • NOTABLE CUSTOMERS

  • Chai Discovery has partnered with pharmaceutical giant Eli Lilly, highlighting its credibility and influence in the biotech industry.

    • KEY METRICS

    ✦ KEY METRIC
  • Total funding raised is $225 million, with the latest Series B round bringing in $130 million and valuing the company at $1.3 billion.

  • The release of Chai-2 has led to double-digit experimental success rates in antibody design, marking a 100-fold improvement over previous methods.

    • COMPETITIVE ADVANTAGE

  • Chai Discovery's AI models, such as Chai-2, offer significant improvements in the success rates of molecular design, setting a new standard in the industry.

  • The company's mission to transform biology from a science into an engineering discipline positions it uniquely in the market, driving innovation and efficiency.

    • MARKET POSITION

  • Founded in 2024 and headquartered in San Francisco, Chai Discovery has rapidly established itself as a pioneering force in AI-driven molecular drug discovery.

  • With a team size of 51, the company combines expertise from leading tech and biotech sectors to maintain a competitive edge.

    • PRODUCT AND TECH

    Chai-2 AI Model

    Chai-2 is an advanced AI model designed for de novo antibody design, significantly improving success rates over previous methods. This innovation is crucial for accelerating the development of new therapeutics.

    AI-Driven Molecular Design

    Chai Discovery utilizes AI to predict and reprogram interactions between biochemical molecules. This approach transforms biology into an engineering discipline, enhancing therapeutic properties.

    Partnership with Eli Lilly

    Chai Discovery's collaboration with Eli Lilly underscores its influence in AI-driven drug development. This partnership highlights the company's industry recognition and potential for impactful therapeutic advancements.

    AI-Powered Drug Discovery

    Leveraging artificial intelligence, Chai Discovery revolutionizes drug discovery by designing novel molecules. This technology streamlines the development process, making it more efficient and effective.

    COMPANY CULTURE

    Values

  • Transform biology from science into engineering

  • Foster innovation through AI-driven solutions

  • Prioritize ethical and responsible AI development

    • Operating Principles

  • Collaborate with industry leaders to drive advancements

  • Embrace a data-driven approach to decision-making

  • Maintain transparency and integrity in all operations

    • Benefits

  • Opportunities to work on cutting-edge AI technologies

  • Collaborative environment with industry experts

  • Access to professional development and learning resources

    • Team Cadence

  • Agile and iterative project management

  • Regular cross-functional team meetings

  • Emphasis on open communication and feedback

    • Learning & Growth

  • Encourage continuous learning and skill development

  • Support for attending industry conferences and workshops

  • Mentorship programs with experienced professionals